Connection

Co-Authors

This is a "connection" page, showing publications co-authored by YU SHEN and ARLENE ODELIA SIEFKER-RADTKE.
Connection Strength

0.948
  1. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. J Urol. 2013 Dec; 190(6):2019.
    View in: PubMed
    Score: 0.459
  2. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7.
    View in: PubMed
    Score: 0.107
  3. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13.
    View in: PubMed
    Score: 0.104
  4. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012; 7(1):e30206.
    View in: PubMed
    Score: 0.102
  5. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004 Aug; 172(2):481-4.
    View in: PubMed
    Score: 0.061
  6. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol. 2004 Jan; 171(1):145-8.
    View in: PubMed
    Score: 0.059
  7. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 2003 Apr; 169(4):1295-8.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.